Method for detecting immune complexes in serum

Claim 2

An IgG mouse antibody, produced by a mouse lymphocyte:myeloma hybridoma cell, which specifically binds to human Clq and human Clq containing complexes but which substantially does not bind to human Cl.

Claim 3

Mouse monoclonal antibody which specifically binds to human Clq and Clq-containing complex in human serum containing human Cl, but which does not detectably bind to human Cl, said antibody of the IgG class and produced by a mouse lymphocyte:myeloma hybridoma cell.

Claim 4

Mouse monoclonal antibody which specifically binds to human Clq and Clq-containing complex in human serum containing human Cl, but which does not detectably bind to human Cl, said antibody of the IgG class and produced by a mouse lymphocyte:myeloma hybridoma cell.

Claim 5

The monoclonal antibody of claim 2 which is produced by hybridoma ATCC HB8327 or HB8328.

Claim 6

A hybridoma capable of producing a mouse monoclonal antibody of the IgG class which specifically binds to human Clq and human Clq-containing complexes, but which does not detectably bind to human Cl.

Claim 7

A hybridoma capable of producing a mouse monoclonal antibody of the IgG class which specifically binds to human Clq and human Clq-containing complexes, but which does not detectably bind to human Cl.

Claim 8

A mouse-mouse hybridoma capable of producing a monoclonal antibody of the IgG class which selectively binds to human Clq and human Clq-containing complex in human serum containing human Cl, but which does not detectably bind to human Cl.

Claim 9

A mouse-mouse hybridoma capable of producing a monoclonal antibody of the IgG class which selectively binds to human Clq and human Clq-containing complex in human serum containing human Cl, but which does not detectably bind to human Cl.

Claim 10

The hybridoma of claim 5 formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse proveiously immunized with human Clq.

Claim 11

The hybridoma of claim 6 which is ATCC HB8327 or HB8328.

Claim 12

A metod for detection or determination of a human Clq-containing complex in a fluid suspected to contain said complex which comprises: (a) providing a mouse monoclonal antibody of the IgG class and produced by a mouse lymphocyte:myeloma hybridoma cell and capable of specifically binding to human Clq and human Clq-containing complexes, but not detectably bind to human Clq, said antibody being attached to a solid phase; (b) contacting a sample of said fluid with said solid phase under conditions to permit an immunological reaction between said human Clq-containing complex and said anti-human-Clq monoclonal antibody; (c) separating the unreacted fluid sample from the solid phase; (d) contacting said solid phase with a labelled second antibody capable of binding to Clq complex which may be bound to the solid phase under conditions to permit an immunological reaction between said second antibody and said bound complesx; (e) separating unreacted second antibody from the solid phase; and (f) detecting or determining said label on either said solid phase or said unreacted second antibody and relating said detection or determination to the presence or quantity of Clq-containing complex in said fluid sample.

Claim 13

A metod for detection or determination of a human Clq-containing complex in a fluid suspected to contain said complex which comprises: (a) providing a mouse monoclonal antibody of the IgG class and produced by a mouse lymphocyte:myeloma hybridoma cell and capable of specifically binding to human Clq and human Clq-containing complexes, but not detectably bind to human Clq, said antibody being attached to a solid phase; (b) contacting a sample of said fluid with said solid phase under conditions to permit an immunological reaction between said human Clq-containing complex and said anti-human-Clq monoclonal antibody; (c) separating the unreacted fluid sample from the solid phase; (d) contacting said solid phase with a labelled second antibody capable of binding to Clq complex which may be bound to the solid phase under conditions to permit an immunological reaction between said second antibody and said bound complesx; (e) separating unreacted second antibody from the solid phase; and (f) detecting or determining said label on either said solid phase or said unreacted second antibody and relating said detection or determination to the presence or quantity of Clq-containing complex in said fluid sample.

Claim 14

The method of claim 8 wherein said fluid is human serum containing native Cl.

Claim 15

The method of claim 8 wherein said second antibody is non-human anti-human IgG.

Claim 16

The method of claim 8 wherein said label is a radioisotope, an enzyme, or a fluorochrome.

Claim 17

The method of claim 8 wherein the selective anti-human-Clq monoclonal antibody is selected from those produced by hybridomas ATCC HB8327 and HB8328.

Claim 18

A test kit for detection of human Clq-containing complex which comprises: (a) a solid phase having attached thereto mouse monoclonal antibody of the IgG class and produced by a mouse lymphocyte-myeloma hybridoma cell, said antibody capable of specifically binding to human Clq and human Clq-containing complexes, but not detectably bind to human Cl; and (b) a container having a labelled second antibody capable of binding to said Clq-containing complex when said complex is bound to the antibody on said solid phase.

Claim 19

A test kit for detection of human Clq-containing complex which comprises: (a) a solid phase having attached thereto mouse monoclonal antibody of the IgG class and produced by a mouse lymphocyte-myeloma hybridoma cell, said antibody capable of specifically binding to human Clq and human Clq-containing complexes, but not detectably bind to human Cl; and (b) a container having a labelled second antibody capable of binding to said Clq-containing complex when said complex is bound to the antibody on said solid phase.

Claim 20

The kit of claim 13 wherein said solid phase is the well of a microtiter plate.

Claim 21

The kit of claim 13 wherein the selective anti-human Clq monoclonal is selected from the antibodies produced by hybridomas ATCC HB8327 and HB8328.

Claim 22

The test kit of claim 13 wherein said labelled second antibody is non-human anti-human IgG.

Claim 23

The test kit of claim 13 wherein the label on said labelled second antibody is selected from the group consisting of radioisotopes, enzymes, and fluorochromes.

Claim 24

The test kit of claim 13 which further comprises means for detecting the label on said second antibody.

Claim 25

The test kit of claim 13 in which the label on said second antibody is an enzyme and which further includes a substrate for said enzyme, which substrate changes color when acted upon by the enzyme.